An Oral Treatment for Ulcerative Colitis
Official title: A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis
Funded at Rise Therapeutics, LLC · NIH-11193481 · Data updated 2026-11-12
This project is creating a new oral medicine that uses natural gut bacteria to calm inflammation for people with inflammatory bowel disease, like ulcerative colitis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rise Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Rockville, UNITED STATES) |
| Project start | September 16, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $704,565 |
| NIH project number | 5SB1DK141356-02 |
| Project ID | NIH-11193481 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be adults aged 21 and older who suffer from inflammatory bowel disease, specifically ulcerative colitis or Crohn's disease.
✕Less likely to help
Patients without inflammatory bowel disease or those under 21 years old would not directly benefit from this specific treatment approach.
What this research studies
We are working to create a new kind of oral medicine that uses the body's own gut bacteria to reduce inflammation in the digestive system. This medicine aims to help people living with inflammatory bowel disease (IBD), which includes conditions like ulcerative colitis and Crohn's disease. Current treatments for IBD can have side effects or stop working over time, so we need safer and more effective options. Our approach focuses on restoring the gut's natural balance and strengthening the intestinal barrier, which is often damaged in IBD. We believe this new therapy could offer a life-changing alternative for those struggling with these chronic conditions.
Why it matters
Potential benefit: If successful, this new oral medicine could provide a safer and more effective treatment option for inflammatory bowel disease, potentially restoring gut health and reducing inflammation.
How similar studies have gone: This project is developing a novel synthetic biology-based cellular medicine, building on the research team's prior findings that a specific protein (SlpA) has anti-inflammatory properties.
Where this research is happening
-
Rise Therapeutics, LLC
Rockville, United States Active
Researchers
- Principal investigator: Fanger, Gary — Rise Therapeutics, LLC
- Study coordinator: Fanger, Gary
Related research
Other NIH-funded projects on the same topics.
-
Oral immunotherapy using engineered bacteria to treat ulcerative colitis
A new, lab-made cellular medicine using friendly gut bacteria aims to reduce inflammation in adults with ulcerative colitis and Crohn’s disease by strengthening the intestinal barrier.
-
A new oral treatment for ulcerative colitis using synthetic biology.
This study is testing a new oral treatment that uses your body's natural gut bacteria to help reduce inflammation and improve symptoms for people with ulcerative colitis, aiming to offer a safer option than some current medications.
-
Outpatient pathway for severe ulcerative colitis in the right care setting
This study tests a safe, outpatient approach using an oral therapy and remote monitoring for people with acute severe ulcerative colitis to avoid hospitalization.
-
Fh15-based therapy to calm inflammation in sepsis and ulcerative colitis
A research project tests a molecule from a parasitic organism (Fh15) to reduce harmful inflammation in adults with sepsis or ulcerative colitis.
-
IMYX-3 treatment for ulcerative colitis
A new therapy approach called IMYX-3 aims to help adults with moderate to severe ulcerative colitis who have not responded well to current treatments.
-
Autoantibodies and ulcerative colitis: how avb6 antibodies may drive disease
This NIH grant aims to understand how antibodies against a gut cell protein (αvβ6) may actively contribute to ulcerative colitis and what that means for future treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.